Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now
Read now
Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park & Chanhyun Park. (2021) Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 381-393.
Read now
Read now
Ariane K. Kawata, William R. Lenderking, Olabimpe R. Eseyin, David Kerstein, Joice Huang, Hui Huang, Pingkuan Zhang & Huamao M. Lin. (2019) Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study. Journal of Medical Economics 22:9, pages 924-935.
Read now
Read now
Zheng-Yi Zhou, Alex Mutebi, Simeng Han, Arielle G. Bensimon, Marie Louise Ricculli, Jipan Xie, Anand Dalal & Ken Culver. (2018) Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. Journal of Medical Economics 21:6, pages 577-586.
Read now
Read now
Articles from other publishers (16)
Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous & William W. L. Wong. (2023) A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). PharmacoEconomics 41:8, pages 945-980.
Crossref
Crossref
Irfan Cicin, Claudio Martin, Carolina Kawamura Haddad, Sang-We Kim, Alexey Smolin, Arif Abdillah & Xue Yang. (2022) ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Critical Reviews in Oncology/Hematology 180, pages 103847.
Crossref
Crossref
Victoria Serelli-Lee, Kazumi Ito, Akira Koibuchi, Takahiko Tanigawa, Takayo Ueno, Nobuko Matsushima & Yasuhiko Imai. (2022) A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. Journal of Personalized Medicine 12:5, pages 669.
Crossref
Crossref
Youwen Zhu, Huabin Hu, Dong Ding, Shuosha Li, Mengting Liao, Yin Shi & Jin Huang. (2021) First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Crossref
Dong DingHuabin HuShuosha LiYouwen ZhuYin Shi, Mengting LiaoJin LiuXu TianAiting Liu & Jin Huang. (2021) Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network 19:10, pages 1141-1147.
Crossref
Crossref
Dong Ding, Huabin Hu, Yin Shi, Longjiang She, Linli Yao, Youwen Zhu, Shan Zeng, Liangfang Shen & Jin Huang. (2021) Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.. The Oncologist 26:2, pages e290-e297.
Crossref
Crossref
Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie & Meaghan Gibbs. (2020) Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
Huabin Hu, Longjiang She, Mengting Liao, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, David P. Carbone & Jin Huang. (2020) Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Dong Ding, Huabin Hu, Mengting Liao, Yin Shi, Longjiang She, Linli Yao, Youwen Zhu, Shan Zeng & Jin Huang. (2020) Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. Advances in Therapy 37:5, pages 2116-2126.
Crossref
Crossref
Longjiang She, Huabin Hu, Mengting Liao, Xuefeng Xia, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, Liangfang Shen, Jin Huang & David P. Carbone. (2019) Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer 138, pages 88-94.
Crossref
Crossref
Haijing Guan, Yanan Sheng, Wanjie Guo, Sheng Han & Luwen Shi. (2019) Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. Advances in Therapy 36:5, pages 1114-1125.
Crossref
Crossref
Christos Chouaid, Lionel Bensimon, Emilie Clay, Aurélie Millier, Laurie Levy-Bachelot, Min Huang & Pierre Levy. (2019) Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer 127, pages 44-52.
Crossref
Crossref
Julia Paik & Sohita Dhillon. (2018) Alectinib: A Review in Advanced, ALK-Positive NSCLC. Drugs 78:12, pages 1247-1257.
Crossref
Crossref
Ashley C. Ly, Jacqueline L. Olin & Morgan B. Smith. (2018)
Alectinib for advanced
ALK
-positive non-small-cell lung cancer
. American Journal of Health-System Pharmacy 75:8, pages 515-522.
Crossref
Crossref
Josh J. Carlson, Kangho Suh, Panos Orfanos & William Wong. (2018) Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics 36:4, pages 495-504.
Crossref
Crossref
Claudio Martín, Andrés F. Cardona, Zyanya Lucia Zatarain-Barrón, Alejandro Ruiz-Patiño, Omar Castillo, George Oblitas, Luis Corrales, Lorena Lupinacci, María Angelina Pérez, Leonardo Rojas, Lisde González, Luis Chirinos, Carlos Ortíz, Mauricio Lema, Carlos Vargas, Carmen Puparelli, Hernán Carranza, Jorge Otero & Oscar Arrieta. (2018) Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices. Oncology 94:5, pages 297-305.
Crossref
Crossref